Printer Friendly

Bruker Daltonics Added to the Russell 2000 Index.

Business/Technology Editors & Health/Medical Writers

BIOWIRE2K

BILLERICA, Mass.--(BW HealthWire)--July 10, 2001

Bruker Daltonics Inc. (NASDAQ: BDAL) announced today that it has been added to the Russell 2000 Index and the broader Russell 3000 Index. Bruker Daltonics went public on NASDAQ in August 2000.

"We are quite pleased to have been included in the Russell 2000 and Russell 3000 indices so shortly after our IPO," said Michael Willett, Bruker Daltonics' Investor Relations Officer. "We believe that our joining the Russell indices will make even more investors aware of Bruker Daltonics' achievements and potential in the life science tools space." He added, "This event represents another validation of our company's vision, strategy and business model."

UBS Warburg's Managing Director of Life Sciences and Biotechnology Research, Geoffrey Harris, said, "Bruker Daltonics has continued its drive to be the leader in mass spectrometry tools for the life sciences industry by keeping its products fresh and by addressing the major bottlenecks in the field. Inclusion in the Russell 2000 Index represents another step in the company's growth."

The Russell 3000 index measures the capitalization of the 3,000 largest public companies in the USA, with the Russell 2000 being the 2000 smaller companies on that list.

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Jul 10, 2001
Words:384
Previous Article:Eicon Offers ACCPAC Server-Based Fax Solution in North America.
Next Article:CertCo Announces Agreements With First International Bank and BankServ.


Related Articles
Bruker Daltonics Confirms Fourth Quarter Expectations.
Bruker Daltonics First Quarter 2001 Product Revenue Increases 55%, Forward Guidance Remains Unchanged.
European Patent Office Revokes Thermo Finnigan's `943 Ion Trap Mass Spectrometry Patent in its Entirety, Announces Bruker Daltonics.
Bruker Daltonics Introduces Suite of New Proteomics Products at the American Society for Mass Spectrometry Conference.
Bruker Daltonics, Applied Biosystems and Indiana University Cross License Significant Mass Spectrometry Patents.
Bruker Daltonics Reports Strong Q2 Life-Science Systems Bookings.
Bruker Daltonics and Thermo Electron Settle Ion Trap Patent Litigation.
Bruker Daltonics Receives Frost & Sullivan's 2002 Product Line Strategy Award.
Frost & Sullivan Presents 2004 Product Line Innovation Award to Bruker Daltonics.
Bruker Daltonics Announces Two Application Notes Demonstrating Its Leading Mass Spectrometry Performance in the 2006 ABRF Proteomics Studies.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters